Clinical observation of GP scheme combined IL-2,IFNα-2b with TACE for the treat-ment of primary liver cancer
Zijun Liao,Guozheng Yu,Yahuan Guo,Yanbing Zhang,Fakai Qiu,Rui Xu
DOI: https://doi.org/10.3969/j.issn.1672-4992.2014.09.39
2014-01-01
Journal of Modern Oncology
Abstract:Objective:Observing the recent curative effect,the long-term survival and adverse reactions of using GP scheme combined IL-2,IFNα-2b with TACE for the treatment of primary liver cancer.Methods:Firstly,to treat 208 cases of primary liver cancer with TACE under DSA guidance.After screening to determine target blood vessels, perfuse gemcitabine 800-1200mg,cisplatin 60-80mg,and then mix Gem 200-400mg,CDDP 20-40mg,interferon 9 ×106 IU,interleukin-2 3 ×106 IU with super liquid Iodine oil 8 -20ml for embolization.Patients were treated at least 3 times.Results:In the 208 cases of PLC,there were 58 cases used TACE treatment for 3 times;88 cases for 4 times;41 cases for 5 times and 12 cases for 6 times.There were 37 cases lacking of blood donor and 171 cases riching in blood donor.The average month of progression of no disease was 7.9 months and the median survial time was 23.3 months.RR(133 cases)was 63.9%,DCR(164 cases)was 78.8%,and stage Ⅱ DCR was the highest (88%).The survival rates of 6 months,1 year,2 years,3 years were 87.5%,74.5%,49.0% and 22.1%,respec-tively.Common adverse reactions were mainly fever,liver pain,nausea or vomiting,loss of appetite,white blood cells, thrombocytopenia,and mostlyⅡ-Ⅲ level,no treatment-related death.Conclusion:Using GP scheme combined IL-2,IFNα-2b with TACE for the treatment of primary liver cancer is a feasible method,which has an reasonable drug selection,better curative effect,and lighter adverse reaction.